Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of ARMO BioSciences Inc (NASDAQ: ARMO) acted responsibly on behalf of investors’ profitability in the planned sale to Eli Lilly and Company.

On May 10, 2018, ARMO BioSciences Inc (NASDAQ: ARMO) and Eli Lilly and Company announced that they had entered into a merger agreement. Under the terms of the merger agreement, Eli Lilly will acquire all outstanding common shares of ARMO for $50.00 per share in cash.    

Based in Redwood City, California, and founded in 2010 ARMO BioSciences Inc develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States.

The investigation is looking to uncover whether ARMO BioSciences Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $75.00 per share.

If you purchased ARMO BioSciences Inc (NASDAQ: ARMO) prior to May 10, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185